Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 21 for “"mRNA-1273"”.
-
IgG antibody responses to SARS-CoV-2 vaccination in Manitoba, Canada
… that vaccination with one dose of Moderna mRNA-1273 elicited higher anti-spike IgG titres overall compared to Pfizer BNT162b2 vaccination, while one dose of Pfizer BNT162b2 followed by a second dose of Moderna mRNA-1273 exhibited higher titres than two doses of Pfizer BNT162b2 or Moderna …
-
Evaluación de la efectividad vacunal para la prevención de la infección por SARS-CoV-2 en personal sanitario
… Evaluar la efectividad de las vacunas BNT162b2 y mRNA-1273 frente al SARS-CoV-2 en los profesionales sanitarios de la Comunidad Valenciana, tras haber completado la pauta vacunal completa de dos dosis, tanto en la prevención de la infección como en la hospitalización, según el tiempo transcurrido …
-
Mathematical model for tripledemic disease (COVID-19, RSV, and Influenza)
… discovery of COVID-19 vaccines such as Moderna (mRNA-1273, Spikevax) and Johnson & Johnson’s, among other vaccines, has reduced COVID-19 cases but has not completely eradicated the disease. In the 2022-2023 season, the world witnessed a ”tripledemic” of Flu, COVID-19, and RSV. We propose …
-
IMMUNITY AGAINST NL63 AS A MODEL FOR SARS-COV-2
… against alphacoronaviruses. We found that mRNA-1273 but not BNT162b2 immunization in mice could induce cross-reactive anti-NL63 antibody responses. Finally, we showcased the utility of our in vitro platform by using it to investigate ACE2 decoys as potential broad-spectrum anti-coronavirus …
-
Methodological Advances in Using Negative Control Endpoints to Improve Vaccine Effectiveness Estimation
… study, which led to qualitative reassessment of mRNA-1273 booster efficacy in this setting. In Part 2, we extend statistical methods for covariate adjustment to incorporate valid negative control endpoints in early-and-late-phase randomized vaccine trials. With particular emphasis on HIV-1 …
-
Humoral Immune Responses following Immunization with SARS-CoV-2 Variant Vaccines
… severe pneumonia, and death. The development of mRNA vaccines targeting the viral spike protein, a crucial mediator for viral entry, contributed to early pandemic control. However, as SARS-CoV-2 evolved, mutations in the spike protein reduced the neutralizing capacity of antibodies elicited by …
-
Addressing Immunological Challenges to COVID-19 Vaccination
… including the BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and ChAdOx1 (Oxford-AstraZeneca) vaccines licensed for use in Australia. An unprecedented push to vaccinate the population is underway, however for certain groups that were not represented in clinical trials, further research is …
-
Εμβόλια έναντι του SARS-CoV-2 από προ-κλινικό στάδιο στην κλινική πράξη
… (BNT162b) των εταιρειών Pfizer/BioNTech, mRNA-1273 της Moderna, το ChAdOx1 της AstraZeneca, και το Ad26.COV2.S της Janssen. Και τα τέσσερα αυτά εμβόλια, από το στάδιο των προ-κλινικών δοκιμών έως και τις κλινικές δοκιμές Φάσης ΙΙΙ παρουσίασαν εξαιρετικό προφίλ ασφάλειας με πολύ καλή …
-
Molecular mechanisms of SARS-CoV-2 variant spike proteins
… protein immunogen in most COVID-19 vaccines (mRNA-1273 [Moderna] and BNT162 [Pfizer] for example). Therefore, mutations within the SARS-CoV-2 S protein impact both viral pathobiology and therapeutic measures to treat viral infection. We hypothesize that variant SARS-CoV-2 spike proteins …
-
DEVELOPING A NOVEL SARS-COV-2 DNA VACCINE TO ELICIT AN ADAPTIVE IMMUNE RESPONSE USING A PADRE MOTIF
… this platform, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), both saw high levels of efficacy and were responsible for the substantial decrease in severe SARS-CoV-2 infection. However, over time due to ongoing mutations to the spike (S) glycoprotein that they each targeted, neutralizing …
-
Covid-19 vaccine safety in special populations
… This dissertation characterizes the safety of mRNA COVID-19 vaccines using post-approval surveillance data in three distinct groups: older adults (≥65 years), pediatric populations (<20 years), and individuals with autoimmune diseases. Additionally, it examines the impact of different …
-
Mechanisms of Antibody-Mediated Protection in Severe Acute Respiratory Syndrome Coronavirus 2 Infection
… virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector …
-
Investigating the Antibody Response to SARS-CoV-2 After Infection or Vaccination
… patients. Moreover, those who received the mRNA-1273 (Moderna) vaccine had higher binding antibody levels and a more durable response over 12 weeks than those receiving BNT162b2 (Pfizer). In contrast, LTCH residents were prioritized for vaccination, and residents were protected from severe …
-
Antibody responses after SARS-CoV-2 infection and vaccination in the UK general population
… linear mixed models, I estimated that the mRNA vaccines (BNT162b2 and mRNA-1273) elicited much higher antibody levels than the adenovirus vaccine (ChAdOx1) and natural infection, but antibodies after infection lasted longer. I also found that people with prior infection had much stronger …
-
CRITICALLY ILL PATIENTS WITH COVID-19 PNEUMONIA: PATHOPHYSIOLOGY, IMPACT OF VACCINE, AND CLINICAL OUTCOME.
… and unvaccinated patients admitted to ICU. Both mRNA (BNT162b2 or mRNA-1273) and adenoviral vaccines (ChAdOx1 or Ad26.COV2.S) resulted associated with significant lower risk of ICU admission. Despite unvaccinated patients admitted to ICU were younger than vaccinated patients, had fewer …
-
THE ROLE OF CD4+ T MEMORY SUBSETS IN HIV INFECTION: IMMUNE RESPONSE IN PEOPLE WITH HIV AND LATENCY ESTABLISHMENT
… group of 14 healthy donors (HDs) who received mRNA-1273 vaccine. PWHIV were stratified according to CD4+ T cell count and CD4/CD8 ratio, two markers of immune reconstitution after ART initiation. The humoral and cellular immune responses to the vaccine were studied using pseudoviruses-based …
-
Redox Physiology of Elite Endurance Athletes
… stress than sea level training. And finally, mRNA COVID-19 vaccination (SPIKEVAX™ (mRNA-1273), Moderna Co., Cambridge, MA, USA) will be associated with a significant but transient increase of oxidative stress and inflammation [i.e, high sensitivity C-Reactive Protein (hsCRP)]. To test the …
-
Micelles and lipid nanoparticles: catalysis and biomedical application.
… patisiran (ONPATTRO®), and BNT162b2 and mRNA-1273, which are LNP-encapsulated mRNA-based vaccines for prevention of COVID-19. Cationic lipids are also considered suitable candidates for RNAi therapeutics delivery. To this end, the present thesis work centers on examining liposome …
-
Evaluation der SARS-CoV-2 spezifischen T Zell Response mittels FACS basierten Assay bei Multiple Sklerose Patienten unter immunmodulatorischer Therapie
… sclerosis = PwMS). Messenger ribonucleic acid (mRNA)-Impfstoffe spielten eine entscheidende Rolle in der Bekämpfung der Covid-19 Pandemie und erwiesen sich bei immunkompetenten Personen als äußerst effektiv. Vor diesem Hintergrund stellte sich die Frage, inwiefern eine Immunisierung gegen severe …
-
Nachweis einer vakzininduzierten T-Zellreaktivität gegen SARS-CoV-2
… „BNT162b2“ („BioNTech / Pfizer“, n = 21) oder „mRNA 1273“ („Moderna / National Institute of Allergy and Infectious Diseases“, n = 7) geimpft wurden. Vier Messzeitpunkte wurden gewählt: „vor der ersten COVID-19 Impfung“ als Kontrollpunkt, jeweils zwei Wochen „nach erster und zweiter Impfungen“, …
Page 1 of 2